Hasford et al of the Collaborative CML Prognostic Factors Project Group developed a prognostic score for patients with chronic myeloid leukemia treated with interferon alfa. The patients studied were collected from 12 institutions and were enrolled in 14 studies.
Exclusion criteria:
(1) > 10% blasts in peripheral blood
(2) blasts + promyelocytes > 30% in peripheral blood
(3) > 15% blasts in bone marrow
(4) blasts + promyelocytes > 50% in bone marrow
(5) extramedullary manifestations
(6) 2 Philadelphia chromosomes, trisomy 8 or isochromosome 17
Parameters used for prognostic score:
(1) age in years
(2) size of spleen
(3) percent blasts in peripheral blood
(4) percent eosinophils in peripheral blood
(5) percent basophils in peripheral blood
(6) platelet count
|
Parameter |
Finding |
Value |
|
age |
< 50 years of age |
0 |
|
|
>= 50 |
1 |
|
spleen |
maximum extent below left costal margin |
number of centimeters |
|
blasts |
percent of blood differential |
from 0 to 100 |
|
eosinophils |
percent of blood differential |
from 0 to 100 |
|
basophils |
< 3% of blood differential |
0 |
|
|
>= 3% |
1 |
|
platelets |
< 1,500,000 per µL |
0 |
|
|
>= 1,500,000 per µL |
1 |
prognostic score =
= 1000 * ((0.6666 * (age value)) + (0.0420 * (spleen value)) + (0.0584 * (blast value)) + (0.0413 * (eosinophils value)) + (0.2039 * (basophils value)) + (1.0956 * (platelets value)))
Interpretation:
• minimum value seen in 908 patients: 0
• maximum value seen in 908 patients: 2,697
• mean value: 916
|
Prognostic Score |
Risk Group |
Median Survival |
5 Year Survival |
|
<= 780 |
low risk |
98 months |
76% |
|
> 780 and <= 1480 |
intermediate risk |
65 months |
55% |
|
> 1480 |
high risk |
42 months |
25% |
Specialty: Hematology Oncology
ICD-10: ,
